(Total Views: 98)
Posted On: 12/16/2024 7:56:33 AM
Post# of 102808
$MNMD MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)
https://www.businesswire.com/news/home/20241216046321/en/
- Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for MM120 Orally Disintegrating Tablet (ODT) 100 µg vs placebo -
- Study builds on positive Phase 2b study results presented at the American Psychiatric Association’s Annual Meeting in May 2024 -
- Topline data from the 12-week double-blind period anticipated in the first half of 2026 -
https://www.businesswire.com/news/home/20241216046321/en/
- Voyage is the first-ever Phase 3 study of lysergide D-tartrate (LSD) with the primary endpoint measuring the change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) score at week 12 for MM120 Orally Disintegrating Tablet (ODT) 100 µg vs placebo -
- Study builds on positive Phase 2b study results presented at the American Psychiatric Association’s Annual Meeting in May 2024 -
- Topline data from the 12-week double-blind period anticipated in the first half of 2026 -
(0)
(0)
